Intra-CSF administration of chemotherapy medications Michael P. GabayJigisha P. ThakkarJ. Lee Villano Review Article 03 June 2012 Pages: 1 - 15
Tumor and non-tumor tissues differential oxidative stress response to supplemental DHA and chemotherapy in rats Nawale HajjajiPierre BessonPhilippe Bougnoux Original Article 18 May 2012 Pages: 17 - 23
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53 E. Gabriela ChioreanSonal SanghaniHiginia Cardenes Original Article 18 May 2012 Pages: 25 - 32
Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies Muneaki ShimadaHiroyuki FujiwaraJunzo Kigawa Original Article 18 May 2012 Pages: 33 - 38
Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine Hannelouise KissowNiels-Erik VibySteen Seier Poulsen Original Article 22 May 2012 Pages: 39 - 48
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes Maryam B. LustbergShubham PantCharles L. Shapiro Original Article 22 May 2012 Pages: 49 - 56
Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors Jin LiYanfei LiuMichiyuki Usami Original Article 22 May 2012 Pages: 57 - 63
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors S. LeongS. G. EckhardtA. C. Lockhart Original Article 24 May 2012 Pages: 65 - 74
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy Solai Elango DamodaranSuresh Chandra PradhanChandrasekaran Adithan Original Article 24 May 2012 Pages: 75 - 81
Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children’s oncology group Alena Y. Z. EdwardsJeffrey M. SkolnikJeffrey S. Barrett Original Article 24 May 2012 Pages: 83 - 94
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors Gordana VlahovicKellen L. MeadowsHerbert I. Hurwitz Original Article 26 May 2012 Pages: 95 - 102
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers Yazdi K. PithavalaYing ChenMichael A. Tortorici Original Article 27 May 2012 Pages: 103 - 112
Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro B. A. KamenA. K. Smith Original Article 27 May 2012 Pages: 113 - 120
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC) Matthew G. FuryEric ShermanDavid G. Pfister Original Article 27 May 2012 Pages: 121 - 128
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas Rachel GrossmanMichelle A. RudekJaishri O. Blakeley Original Article 27 May 2012 Pages: 129 - 139
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer Mohamad FaridBalram ChowbaySimon Yew Kuang Ong Original Article 31 May 2012 Pages: 141 - 150
Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics Pradeep B. LukkaJames W. PaxtonBruce C. Baguley Original Article 03 June 2012 Pages: 151 - 160
Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study N. KentepozidisA. SoultatiV. Georgoulias Original Article 03 June 2012 Pages: 161 - 168
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer N. KarachaliouN. ZirasD. Mavroudis Original Article 06 June 2012 Pages: 169 - 176
The minimal impact of food on the pharmacokinetics of ridaforolimus Mark StrohXiaodong LiMarian Iwamoto Original Article 06 June 2012 Pages: 177 - 182
Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers Gavin ChoyRajashree Joshi-HangalSanjeev Redkar Clinical Trial Report 15 February 2012 Pages: 183 - 190
A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor Richat AbbasBruce A. HugDaryl Sonnichsen Clinical Trial Report 15 March 2012 Pages: 191 - 199
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors Abdulateef O. AregbeEric A. ShererRobert R. Bies Short Communication Open access 27 March 2012 Pages: 201 - 205
The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response Trevor G. GlarosLuke H. StockwinDianne L. Newton Short Communication 21 April 2012 Pages: 207 - 212